BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 17879017)

  • 1. [Diagnostic algorithm in chronic myeloproliferative diseases (CMPD)].
    Haferlach T; Bacher U; Kern W; Schnittger S; Haferlach C
    Med Klin (Munich); 2007 Sep; 102(9):770-7. PubMed ID: 17879017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos.
    Tefferi A; Thiele J; Vardiman JW
    Cancer; 2009 Sep; 115(17):3842-7. PubMed ID: 19472396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modern diagnostics in chronic myeloproliferative diseases (CMPDs).
    Haferlach T; Kern W; Schnittger S; Schoch C
    Ann Hematol; 2004; 83 Suppl 1():S59-61. PubMed ID: 15124674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
    Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information.
    Bacher U; Haferlach T; Kern W; Hiddemann W; Schnittger S; Schoch C
    Ann Hematol; 2005 Apr; 84(4):250-7. PubMed ID: 15692838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms.
    Tefferi A; Vardiman JW
    Leukemia; 2008 Jan; 22(1):14-22. PubMed ID: 17882280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
    Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histological and molecular classification of chronic myeloproliferative disorders in the age of JAK2: persistence of old questions despite new answers.
    Hussein K; Bock O; Kreipe H
    Pathobiology; 2007; 74(2):72-80. PubMed ID: 17587878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers.
    Haferlach T; Bacher U; Kern W; Schnittger S; Haferlach C
    Ann Hematol; 2008 Jan; 87(1):1-10. PubMed ID: 17938925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations in the JAK2 and MPL genes and their correlation to clinical parameters in patients with chronic myeloproliferative disease.
    Bojko P; Abenhardt W; Schnittger S; Haferlach T
    Onkologie; 2009 Apr; 32(4):191-5. PubMed ID: 19372714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytogenetic and molecular aspects of Philadelphia negative chronic myeloproliferative disorders: clinical implications.
    Panani AD
    Cancer Lett; 2007 Sep; 255(1):12-25. PubMed ID: 17383090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in understanding and management of myeloproliferative neoplasms.
    Vannucchi AM; Guglielmelli P; Tefferi A
    CA Cancer J Clin; 2009; 59(3):171-91. PubMed ID: 19369682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders.
    Pikman Y; Levine RL
    Curr Opin Oncol; 2007 Nov; 19(6):628-34. PubMed ID: 17906464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical study on relationship between JAK2 V617F mutation and chronic myeloproliferative disorders].
    Zhang Y; Li L; Nie L; Yu Y; Yang YH; Zhang ZQ; Yang L; Xu SC; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2008 Feb; 29(2):105-9. PubMed ID: 18681311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The saga of JAK2 mutations and translocations in hematologic disorders: pathogenesis, diagnostic and therapeutic prospects, and revised World Health Organization diagnostic criteria for myeloproliferative neoplasms.
    Smith CA; Fan G
    Hum Pathol; 2008 Jun; 39(6):795-810. PubMed ID: 18538168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathology consultation on myeloproliferative neoplasms.
    Schmidt AE; Oh ST;
    Am J Clin Pathol; 2012 Jul; 138(1):12-9. PubMed ID: 22706852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy.
    Tefferi A
    Am J Hematol; 2008 Jun; 83(6):491-7. PubMed ID: 18429051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JAK2 and MPL gene mutations in V617F-negative myeloproliferative neoplasms.
    Siemiatkowska A; Bieniaszewska M; Hellmann A; Limon J
    Leuk Res; 2010 Mar; 34(3):387-9. PubMed ID: 19643476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
    Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.
    Hussein K; Brakensiek K; Buesche G; Buhr T; Wiese B; Kreipe H; Bock O
    Ann Hematol; 2007 Apr; 86(4):245-53. PubMed ID: 17262192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.